PDB25: COST ANALYSIS OF DIABETES TREATMENT WITH GLARGINE INSULIN OR NPH INSULIN IN SPAIN  by Rubio-Terrés, C et al.
336 Abstracts
cardiologists. Eighty-ﬁve percent of investigators were
afﬁliated with hospitals with over 101 beds. Sixty-ﬁve
percent and 72% of sites were public and teaching hos-
pitals, respectively. We found signiﬁcant variation among
physician/site characteristics across geographic regions.
Sixteen percent of US respondents were cardiologists,
52% in Latin America, 26% in Eastern Europe, 7% in
Europe, 4% in Africa and Asia Paciﬁc, and 0% in Canada
(p = <.0001). Twenty-nine percent of US investigators
were afﬁliated with public hospitals as compared to
100% in Canada, 97% in Eastern Europe, 88% in
Europe, 87% in Asia Paciﬁc, 53% in Latin America, and
22% in Africa (p = <.0001). CONCLUSION: We assessed
physician/site characteristics in a clinical trial setting and
determined that characteristics vary by geographic region.
Therefore, it is important to measure physician and site
characteristics to avoid the potential for confounding in
the economic evaluation of the NAVIGATOR trial.
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OBJECTIVES: Type 2 Diabetes is associated with severe
complications such as heart disease, stroke, high blood
pressure, kidney disease etc. Approximately 17 million
people suffer from diabetes accounting to 6.2% of the
population in the United States. According to the 
American Diabetes Association, the total cost of diabetes
to the society is 98 billion dollars. Type 2 diabetes
accounts for about 90–95% of all the diagnosed cases of
diabetes. This study examines the various physician and
patient factors, which inﬂuence the diagnostic test pre-
scribing for diabetes in ambulatory patients. METHODS:
Patient factors such as age, sex, race, geographical loca-
tion and payment source and Physician factors such as
specialty, geographic location and referral status were
used to determine their inﬂuence on the number of diag-
nostic tests prescribed. Data from the National Ambula-
tory Medical Care Survey (NAMCS) 2000 were utilized.
Patients with principal diagnosis of type 2 diabetes (ICD-
9-CM code 250.00) were analyzed using multiple linear
and binomial logit regression models. RESULTS: The
numbers of diagnostic tests performed were independent
of patients’ age, sex and geographic region (R2 = 0.117).
Blacks and Hispanic patients were prescribed more diag-
nostic tests compared to other races (R2 = 0.346).
Patients with Federal source of payments (Medicaid and
Medicare) were prescribed more diagnostic tests than
other patients (R2 = 0.245). Numbers of diagnostic tests
were not inﬂuenced by whether the patient was referred
(R2 = 0.037). Various physician specialties also had no
inﬂuence on the number of diagnostic tests prescribed (R2
= 0.054). CONCLUSIONS: The numbers of diagnostic
tests prescribed are signiﬁcantly inﬂuenced by patients’
race and source of payments. Diagnostic tests constitute
a signiﬁcant portion of the cost of diabetes therapy.
Further research, reviewing the causes of the signiﬁcant
differences seen in this study would help control/reduce
the cost of diabetes therapy.
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OBJECTIVES: A pharmacoeconomic analysis was
carried out comparing a long-acting analog of human
insulin, insulin glargine (once-daily injection), and NPH
human insulin (twice-daily injections) in patients with
Type 1 (DM1) and Type 2 (DM2) diabetes mellitus in
Spain. METHODS: Retrospective analysis using a cost-
offset model, from the perspective of the National Health
System in Spain. The following short term (1 year) health
costs of diabetes mellitus were used in the model: glargine
or NPH insulin treatment, use of lispro insulin, nurse
home visits, severe hypoglycemia episodes, test strips for
glucose control and disposable needles. The utilisation of
resources was estimated from two clinical trials compar-
ing insulin glargine (Lantus) and NPH human insulin in
patients with DM1 and DM2 and from Spanish sources,
and the unit costs from a Spanish health costs database.
RESULTS: The use of glargine insulin instead of NPH
insulin would result in an annual saving of €234.75 and
€89.47 for a patient with DM1 and DM2, respectively.
Although the acquisition cost of glargine insulin is higher,
yearly savings can be achieved compared to NPH insulin
in the remaining costs analysed especially in the use of
less test strips (€198.85 in DM1 and DM2), less costs in
nurse home visits (€83.22 in DM1 and DM2), lower
doses of lispro insulin (€49.78 in DM1), lower incidence
of severe hypoglycemia (€6.91 and €1.33 in DM1 and
DM2) and lower costs in insulin needles (5.02 euros in
DM1 and DM2). CONCLUSIONS: A comprehensive
analysis of the costs associated with insulin treatment
shows that switching to once-daily insulin glargine from
NPH insulin reduces Health System costs for treating
Type 1 and Type 2 diabetic patients in Spain.
DIABETES—Quality of Life/Preference Based
Outcomes
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OBJECTIVE: Our objective was to examine the scores
and reproducibility of a 47 item Quality Of Life ques-
